You are here: Home » Current Affairs » Coronavirus » News
Business Standard

Brazil approves Pfizer's coronavirus vaccine, but has none to use

It is the first coronavirus shot to receive full approval in Brazil, regulator Anvisa said. Vaccines developed by AstraZeneca and China's Sinovac Biotech Ltd, have only been approved for emergency use

Topics
Brazil | Coronavirus Vaccine | Pfizer

Reuters 

Pfizer
The approval is good news for a country whose immunization campaign has been plagued by delays and political squabbling

has fully approved the COVID-19 vaccine developed by Inc and BioNTech SE , its health regulator said on Tuesday, though a dispute over a supply deal means it has none to start an immunization program with.

It is the first coronavirus shot to receive full approval in Brazil, regulator Anvisa said. Vaccines developed by and China's Sinovac Biotech Ltd, have only been approved for emergency use.

The approval is good news for a country whose immunization campaign has been plagued by delays and political squabbling.

However, it is unclear whether this will pave the way for a supply deal of a highly effective shot that is being rolled out globally.

"We hope to be able to move forward in our negotiations with the Brazilian government to support the immunization of the country's population," Pfizer's boss Marta Diez said in a statement, without giving further details.

Brazil's Health Ministry did not respond to a request for comment.

President Jair Bolsonaro has criticized the terms of a deal proposed by Pfizer, saying it is overly onerous as it exempts the U.S. firm from potential liability for unforeseen problems.

has said other countries, including Brazil's neighbors in Latin America, have agreed to those terms.

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Tue, February 23 2021. 20:40 IST
RECOMMENDED FOR YOU